Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotype-tailored Lansoprazole in Children With Uncontrolled Asthma
NCT03015610Phase 3Completed
- Start
- Oct 2017
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma and gastroesophageal reflux disease (GERD) comparing Genotype-guided Lansoprazole with Placebo (2 arms). Primary endpoint: Asthma Control Questionnaire at 26 weeks. Started Oct 2017; status: completed.
02
Drugs
lansoprazole
03
Conditions
asthmagastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03015610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03015610.